CEO Ron Bentsur is scheduled to speak at 10:30 a.m. ET in New York; Nuvectis says a webcast will be available in the ...

Opportunities center on targeted complement inhibitors, biologics, small molecules, RNA and gene therapies for rare diseases across ophthalmology, hematology and immunology.Dublin, Sept. 16, 2026 ...

Paroxysmal nocturnal hemoglobinuria has long been one of hematology’s cruelest puzzles: a rare, acquired stem-cell mutation that leaves red blood cells defenseless against the body’s own com ...

Ratey claims movement is cognitive medicine that lifts learning, calms anxiety and depression, and slows decline through ...

A candidate-gene study of Chinese Han children finds nominal links between complement-related gene variants and severe ...

Ionis Pharmaceuticals Inc. and partner Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA ...

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

How the Reds set up their catching hierarchy this winter will be closely watched.

SpaceX’s $8B deal sparked selloff in major telecom stocks - but is it warranted? Why Micron Technology deserves its strong ...

As new credit models learn from spending and cash-flow patterns, the challenge is no longer producing an explanation. It is ...

Canada's competition watchdog says a healthy market at home is key to strengthening the economy as trade tensions with the ...

Despite some market underperformance, Cencora's specific business and macro fundamentals remain supportive. Read why COR ...